BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND H3F3A, P84243, H3_3B, MGC87783, MGC87782, H3F3, H3_3A, ENSG00000163041, 3020 AND Treatment
10 results:

  • 1. Cycle-generative adversarial network-based bone suppression imaging for highly accurate markerless motion tracking of lung tumors for cyberknife irradiation therapy.
    Mochizuki Z; Saito M; Suzuki T; Mochizuki K; Hasegawa J; Nemoto H; Satani K; Takahashi H; Onishi H
    J Appl Clin Med Phys; 2024 Jan; 25(1):e14212. PubMed ID: 37985163
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors.
    Cao GZ; Ma LY; Zhang ZH; Wang XL; Hua JH; Zhang JH; Lv Y; Zhang SB; Ou J; Lin WC
    Acta Pharmacol Sin; 2023 Apr; 44(4):841-852. PubMed ID: 36253561
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre.
    Vari S; Riva F; Onesti CE; Cosimati A; Renna D; Biagini R; Baldi J; Zoccali C; Anelli V; Annovazzi A; Covello R; Ascione A; Casini B; Ferraresi V
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142631
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Differential proteome and functional analysis of NSCLC cell lines in response to Tualang honey treatment.
    Amran N; Abdul-Rahman PS
    J Ethnopharmacol; 2022 Jul; 293():115264. PubMed ID: 35398242
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
    Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
    Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Prognostic factor analysis of patients with unresectablelung squamous cell carcinoma].
    Gao X; Li Z; Shao XY; Liu XM; Liu C; Liu YP; Qu XJ; Zhang LY
    Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):569-573. PubMed ID: 34034477
    [No Abstract]    [Full Text] [Related]  

  • 7. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab.
    Tsukamoto S; Righi A; Vanel D; Honoki K; Donati DM; Errani C
    Jpn J Clin Oncol; 2017 Nov; 47(11):1090-1096. PubMed ID: 29048579
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. h3f3a mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
    Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
    Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Giant cell tumor of bone: current treatment options.
    Skubitz KM
    Curr Treat Options Oncol; 2014 Sep; 15(3):507-18. PubMed ID: 24788576
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee.
    Matteson EL; Hickey AR; Maguire L; Tilson HH; Urowitz MB
    J Rheumatol; 1991 Jun; 18(6):809-14. PubMed ID: 1895261
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.